Providing medical cannabis formulations and
dose delivery systems for German patients.

Corporate Profile

Opportunity

Europe will be the world’s largest medical cannabis (MMJ) market, with Germany setting the standard for its role in healthcare and insurance. Strong demand and high prices make Germany a lucrative market – especially as medication is covered by government insurance.

Challenges

Unique legal and cultural frameworks in each European country and the Canadian experience provides limited insight on how the German or European markets will develop. German companies will ultimately dominate the European industry.

Strategy

AMP will import MMJ from a EU GMP-certified Canadian LP and distribute to German pharmacies and wholesalers through AMP’s partners by Q4, 2019.  Develop drug formulations, dose delivery systems in collaboration with patients, doctors, pharmacists and under the direction of German universities for sale by 2021.

Cannabis Market and New Opportunities

In just six months of 2018, the European cannabis industry has grown more than in the previous five years. Over six new countries have announced legalization, patient numbers have grown by 40% month on month and over €150m has been invested in the European industry alone.

Facts and Figures

Cannabis is a new industry that some believe could surpass some alcohol segments in sale at maturity.

%

Increase in European acreage for medical cannabis between 2015 and 2016

%

All European production is accounted for by France, the main producer of hemp in Europe

The Directors

AMP Alternative Medical Products Limited is a biopharmaceutical company developing cannabis formulations and
dose delivery systems for the German medical market and with offices in Berlin, Germany and Vancouver, Canada.

AMP’s board and management have over 25-years experience in industrial and regulated German industries
including pulp and paper, plastics, real estate, renewable energy, 30-years experience in European commercial and
merchant banking and over 30-years experience in Canadian public company governance experience.

 

Dr. Stefan Feuerstein (DE)

Proposed Director and President, Managing Director of AMP GmbH

Director, Taiga Atlas plc, Formerly, MD of IIC Industrial Investment Council GmbH, investment agency for Eastern Germany, and TLW Thüringer Landwirtschafts Forderungsgesellschaft, German State of Thuringia economic development agency.

Mr. Alex Blodgett (CDN)

Director. Proposed CEO

Director, Taiga Atlas plc.  Over 15-years Canadian public company board and executive experience.  Formerly, with Gordon Capital and Banker Trust.

Mr. Claudio Morandi (CH)

Proposed Director and CFO. Director AMP GmbH

Chairman, Taiga Atlas plc. Formerly, SVP of MFC Merchant Bank Ltd., a specialty trade and structured finance bank and a subsidiary of MFC Bancorp Ltd., a Nasdaq listed merchant bank.

Mr. Ken MacLeod (CDN)

Independ Director

Over 25-years board and executive experience in Canadian public companies predominately in  renewable energy and mining projects in Asia and North America.

AMP Alternative Medical Products GmbH

Providing medical
cannabis formulations
and dose delivery systems
for German patients.

AMP-EU

AMP Alternative Medical Products Limited is a biopharmaceutical company developing cannabis formulations and dose delivery systems for the German medical market.